334 related articles for article (PubMed ID: 20480365)
1. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy.
Coe D; Begom S; Addey C; White M; Dyson J; Chai JG
Cancer Immunol Immunother; 2010 Sep; 59(9):1367-77. PubMed ID: 20480365
[TBL] [Abstract][Full Text] [Related]
2. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.
Ramirez-Montagut T; Chow A; Hirschhorn-Cymerman D; Terwey TH; Kochman AA; Lu S; Miles RC; Sakaguchi S; Houghton AN; van den Brink MR
J Immunol; 2006 Jun; 176(11):6434-42. PubMed ID: 16709800
[TBL] [Abstract][Full Text] [Related]
4. In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules.
Nishioka T; Nishida E; Iida R; Morita A; Shimizu J
Immunol Lett; 2008 Dec; 121(2):97-104. PubMed ID: 18930767
[TBL] [Abstract][Full Text] [Related]
5. Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted.
Kim YH; Shin SM; Choi BK; Oh HS; Kim CH; Lee SJ; Kim KH; Lee DG; Park SH; Kwon BS
J Immunol; 2015 Nov; 195(10):4721-9. PubMed ID: 26423152
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ
J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849
[TBL] [Abstract][Full Text] [Related]
7. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
[TBL] [Abstract][Full Text] [Related]
8. GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells.
Liao G; Nayak S; Regueiro JR; Berger SB; Detre C; Romero X; de Waal Malefyt R; Chatila TA; Herzog RW; Terhorst C
Int Immunol; 2010 Apr; 22(4):259-70. PubMed ID: 20139172
[TBL] [Abstract][Full Text] [Related]
9. Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma.
Heier I; Hofgaard PO; Brandtzaeg P; Jahnsen FL; Karlsson M
Clin Exp Immunol; 2008 May; 152(2):381-7. PubMed ID: 18341610
[TBL] [Abstract][Full Text] [Related]
10. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
Schaer DA; Budhu S; Liu C; Bryson C; Malandro N; Cohen A; Zhong H; Yang X; Houghton AN; Merghoub T; Wolchok JD
Cancer Immunol Res; 2013 Nov; 1(5):320-31. PubMed ID: 24416730
[TBL] [Abstract][Full Text] [Related]
11. Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein(high), Foxp3-expressing CD25+ and CD25- regulatory T cells.
Ono M; Shimizu J; Miyachi Y; Sakaguchi S
J Immunol; 2006 Apr; 176(8):4748-56. PubMed ID: 16585568
[TBL] [Abstract][Full Text] [Related]
12. Blockade of GITR-GITRL interaction maintains Treg function to prolong allograft survival.
Kim JI; Sonawane SB; Lee MK; Lee SH; Duff PE; Moore DJ; O'Connor MR; Lian MM; Deng S; Choi Y; Yeh H; Caton AJ; Markmann JF
Eur J Immunol; 2010 May; 40(5):1369-74. PubMed ID: 20148423
[TBL] [Abstract][Full Text] [Related]
13. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
[TBL] [Abstract][Full Text] [Related]
14. Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity.
Cho JS; Hsu JV; Morrison SL
Cancer Immunol Immunother; 2009 Jul; 58(7):1057-69. PubMed ID: 19018533
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
16. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors.
Zhou P; L'italien L; Hodges D; Schebye XM
J Immunol; 2007 Dec; 179(11):7365-75. PubMed ID: 18025180
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 binding to CD4 on CD4+CD25+ regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: an additional mechanism of immunosuppression.
Ji J; Cloyd MW
Int Immunol; 2009 Mar; 21(3):283-94. PubMed ID: 19208751
[TBL] [Abstract][Full Text] [Related]
18. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-induced tumour necrosis factor receptor family-related receptor signalling exacerbates hapten-induced colitis by CD4+ T cells.
Lee SK; Choi BK; Kim YH; Kang WJ; Kim KH; Sakaguchi S; Suh JH; Kim TY; Kwon BS
Immunology; 2006 Dec; 119(4):479-87. PubMed ID: 17177830
[TBL] [Abstract][Full Text] [Related]
20. Engagement of glucocorticoid-induced TNF receptor costimulates NKT cell activation in vitro and in vivo.
Kim HJ; Kim HY; Kim BK; Kim S; Chung DH
J Immunol; 2006 Mar; 176(6):3507-15. PubMed ID: 16517719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
